ArticleScientific reports2026
Collagen gene expression profiles predict recurrence and progression of DCIS to IDC.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a major cause of cancer-related morbidity and mortality globally. Ductal carcinoma in situ (DCIS) is a non-invasive precursor to invasive ductal carcinoma (IDC), and understanding the molecular mechanisms driving this transition is critical. This study explores the role of collagen genes (COL1A1, COL1A2, COL3A1, COL5A2) in extracellular matrix (ECM) remodeling and tumor progression. Pathology samples were collected from patients at Rasoul Akram, Asia, and Khatam Al-Anbia Hospitals (2013-2023), including 42 cases (recurrent DCIS and IDC) and 32 controls (primary DCIS without recurrence). RNA was extracted, reverse transcribed, and analyzed via real-time PCR to assess collagen gene expression. Statistical analyses, including ROC curve analysis, were performed to evaluate the predictive performance of collagen gene expression. Results revealed significant upregulation of COL1A1, COL1A2, COL3A1, and COL5A2 in the case group, with fold increases of 9.71, 5.38, 3.16, and 4.63, respectively (p ≤ 0.05). Overexpression was most pronounced in ER-negative, PR-negative, and high Ki67 subtypes, indicating a link to aggressive tumor behavior. ROC analysis demonstrated the potential predictive utility of collagen gene expression profiles, with AUC values ranging from 0.765 to 0.859. These findings underscore the role of collagen genes in breast cancer progression, highlighting their potential as predictive biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.